

REGISTRATION

Academic - € 60
 FlandersBio, BioWin or BMM members - € 100
 Other - € 160

Registration is available on
www.flandersbio.be/tissue-engineering

Deadline: Tuesday, 30 September 2009

VENUE

VBO building
 Rue Ravenstein 4
 1000 Brussels
 BELGIUM

Tel: +32 2 515 09 11
www.vbo.be

Parking facilities:
www.interparking.com

FlandersBio is the umbrella organisation for the Life Sciences sector in Flanders. A dynamic non-profit, fee based organisation with 160 members that supports and facilitates the sector's sustained development.

The FlandersBio network brings together companies with innovative, R&D-driven activities in the life sciences – companies that are for example developing biopharmaceuticals, medical technologies or agricultural or industrial biotech products. Our network welcomes companies with production activities based in Flanders as well as academic research institutes and providers of capital, services and technologies to the life sciences community.

info@flandersbio.be



FlandersBio
 Rijvisschestraat 118b1, 9052 Zwijnaarde Belgium
 Tel: +32 9 241 80 41 - Fax: +32 9 241 80 40
hilde.vanraemdonck@flandersbio.be
 Project Manager Medical Technology

www.flandersbio.be

STRATEGIC PARTNERS



Tissue Engineering

Brussels
 1 October 2009


Novel Tissue Engineering Opportunities

'Novel Tissue Engineering opportunities' focuses on scientific expertise and business & regulatory experience on cell-therapy medicinal products, tissue-engineered products as well as related medical devices.

The seminar has a transdisciplinary approach covering talks from material science and chemistry to biology and medicine. The programme includes presentations by experts from research institutes such as Catherine Verfaillie, Director Stem Cell Institute K.U.Leuven, as well as presentations by company representatives.

Through a partnership with BioWIN and BMM, Walloon and Dutch companies will be present, allowing extended networking. Via the 'getting connected formula', you will get the opportunity to present your company and company focus and to discuss current needs.

The seminar is targeted at academic experts, industry experts as well as business developers, financial experts and service providers. Please feel welcome to gain insight into the current expertise and potential in Flanders and to join us in taking this expertise and potential to the next level.



FlandersBio Seminar Programme

	TOPIC	SPEAKERS
08.30-09.30	Registration & welcome coffee	
09.30-09.40	Introduction	Ann Van Gysel, General Manager FlandersBio
09.40-10.20	Keynote: Stem cells combined with tissue engineering possibility for therapeutic use and pharmacological industry	Catherine Verfaillie, Director Stem Cell Institute K.U.Leuven
10.20-10.40	Nanotechnology and Stem Cells as Flexible Imaging Tools	Kris Verstreken, Program Director Human++ IMEC
10.40-11.00	Cross linkable biodegradable polymers as scaffolds for bone tissue engineering	Etienne Schacht, Prof. Laboratory of Organic Chemistry UGent
11.00-11.30	Coffee break	
11.30-11.50	Regulatory & Reimbursement perspectives	Wilfried Dalemans, VP Regulatory Affairs and Corporate Quality Tigenix
11.50-12.10	C-Cure Clinical Trial: a cellular therapy for heart regeneration	Sophie Henry, VP Clinical RA & QA Cardio 3
12.10-12.30	Intelligent Partnerships in Tissue Engineering	Marc Van Gastel, Director Deloitte
12.30-13.30	Lunch	
13.30-13.50	Universal Donor Adult Stem Cell Products: Development and Characterization	Jef Pinxteren, Head R&D Regenesys
13.50-14.10	Development of an Advanced Therapy Medicinal Product for cartilage repair & regeneration	Peter Tomme, R&D Director Tigenix
14.10-14.30	Collaboration opportunities with other regions	BioWIN & BMM
14.30-15.00	Dessert buffet	
15.00-17.00	Getting Connected : Partnering & Discussion in breakout rooms Partners: BMM & BioWIN Topics: <u>Stem Cells (Imaging & Homing)</u> - Moderator: Catherine Verfaillie, Stem Cell Institute, K.U.Leuven <u>Scaffolds (Biomaterials & Engineering)</u> - Moderator: Etienne Schacht, Lab. of Organic Chemistry UGent <u>Legislation</u> - Moderator: Wilfried Dalemans Tigenix	Keynote presentation by Catherine Verfaillie, Director Stem Cell Institute K.U.Leuven Catherine Verfaillie's research focuses on normal hematopoietic stem cells and leukemic stem cells. She has also studied pluripotent stem cells, and described for the first time stem cells from postnatal origin with greater potency, named multipotent adult progenitor cells or MAPCs. The interest of the Verfaillie lab at K.U.Leuven currently focuses on understanding what regulates selfrenewal and differentiation of hematopoietic and pluripotent stem cells, and testing the possible use of stem cell based and stem cell derived therapies in animal models of hematopoietic, cardiovascular, liver and metabolic (diabetes) disorders. For more info about the speakers, visit www.flandersbio.be/tissue-engineering

SPONSOR



ReGenesys is a wholly-owned subsidiary of Athersys, a publicly held biotechnology company located in Cleveland, Ohio. The company has established master cell banks and successfully produced a cGMP cell product by FDA guidelines. ReGenesys is focused on establishing additional stem cell banks and European manufacturing capability.

www.regenesys.eu

COLLABORATING CLUSTERS



BioWin's ambition is to bring together Walloon stakeholders committed to promoting innovation and training in the field of biotechnology in health care.

www.biowin.org



The DutchBioMedical Materials program (BMM) is a public private partnership of universities, university medical centers, companies and patient organizations, dedicated to the development of novel BioMedical Materials and their applications.

www.bmm-program.nl